Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

NCT06517953 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic
EGFR G719X
EGFR L861Q
EGFR S768I

Interventions

DRUG: Icotinib
DRUG: Befotertinib

Sponsor

Sun Yat-sen University